pwrm Latest News

Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases,

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators.

PWRM.OB, HMA, RDN, & NVE: NV Energy, Inc. Reports Third Quarter Earnings

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas.

NRO, ULU, SA, & PWRM.OB: Drills Upgrading Large Resource at Seabridge Gold's Courageous Lake Project

Power3 Medical Products (OTCBB: PWRM.OB) BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

PWRM BC-SeraPro was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.BC-SeraPro™ is an ideal diagnostic test to evaluate breast cancer abnormalities

Power3 Medical Products (OTCBB: PWRM.OB) BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment

PWRM.OB, ILMN, & VSYM.OB: ILMN has recently reported the production of the Eco Real-Time PCR System

The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

BC-SeraPro™ could detect the disease at a point when treatment is more effective, less expensive, or both.

PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease.

PWRM, MNTA, & SNY: Raul E. Kohan will be appointed Chief Executive Officer

Power3 Medical Products Inc., (OTCBB: PWRM.OB) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies

MNTA, GENZ, & PWRM.OB: Biotech Stocks: Onyx, Genzyme, Momenta in spotlight

GENZ, PWRM, & SNY: Blink on Friday And Miss Massive Biotech Spikes

PWRM’s NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases.

PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease

PWRM, ILMN, & CAH: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at Hold

AFFX, LIFE, & OTC:PWRM: Affymetrix Launches Axiom Custom Genotyping Arrays Utilizing World's Largest Validated SNP Database

SNY, GSK, & OTC:PWRM: Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery.

PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests

PWRM.OB is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies.

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout.

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information.

BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

PWRM is now available for $0.039 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

Amgen Inc. is a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States

Cyclacel's cancer drug gets FDA orphan status: PWRM, SIGA, & CYCC

Crawford, Molecular Insight Pharmaceuticals: Biggest Price Decliners (CRDB, MIPI)

PWRM strives to become the premier biotech company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technology, world class quality procedures and superior research methodologies.

PWRM is still available for $0.036 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

PWRM is now available for $0.04 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

PWRM is now available for $.04 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. A breakout could be an indicator of possible momentum.

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.

PWRM is still available for $0.0375 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout.

Fascinating Breakthroughs In Pharmaceutical Research Companies: PWRM, SIGA, & CYCC

DrStockPick.com is pleased to announce its Daily Stocks to Watch!

NNVC Invading Into VIRL and PWRM’s areas of research

DrStockPick.com is pleased to announce its Daily Stocks to Watch!

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers.

Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits

Albany Molecular Research Inc. announced today that its board of directors has approved a new share repurchase program of up to $10 million

Power 3 Medical Products Inc. (OTC BB: PWRM.OB) recently has filed for 2 patent protection, one on Alzheimer’s disease specific differential diagnosis.